Home / Recalls / Central Admixture Pharmacy Services, Inc. / D-0720-2023

D-0720-2023 Class II Terminated

Recalled by Central Admixture Pharmacy Services, Inc. — Allentown, PA

Recall Details

Product Type
Drugs
Report Date
May 31, 2023
Initiation Date
April 28, 2023
Termination Date
June 22, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
27780 bags

Product Description

vancomycin added to 0.9% sodium chloride, 1.25 g/250 mL* (5 mg/mL), 250 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., 6580 Snowdrift Rd., Ste 100, Allentown, PA 18106, NDC 71285-6074-1.

Reason for Recall

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Distribution Pattern

Nationwide in the USA.

Code Information

Lot # 37-883407, 37-883436, Exp 05/01/2023; 37-883796, 37-883797, 37-883800, 37-883802, 37-883806, Exp 05/02/2023; 37-884162, 37-884163, Exp 05/03/2023; 37-885332, 37-885336, 37-885337, Exp 05/08/2023; 37-885749, 37-885753, 37-885755, Exp 05/09/2023; 37-886008, 37-886027, 37-886031, 37-886035, Exp 05/10/2023; 37-886273, 37-886274, 37-886275, Exp 05/11/2023; 37-887448, 37-887457, Exp 05/16/2023; 37-887765, 37-887772, 37-887775, Exp 05/17/2023; 37-888062, 37-888072, Exp 05/18/2023; 37-888811, 37-888817, Exp 05/22/2023; 37-889193, 37-889208, 37-889210, Exp 05/23/2023; 37-889450, 37-889451, 37-889454, Exp 05/24/2023; 37-890940, 37-890941, 37-890952, Exp 05/30/2023; 37-891137, 37-891138, 37-891139, Exp 05/31/2023; 37-892633, 37-892634, 37-892635, Exp 06/06/2023; 37-892934, 37-892961, 37-892964, 37-892965, Exp 06/07/2023; 37-893524, Exp 06/11/2023; 37-893993, 37-893996, Exp 06/12/2023; 37-894465, 37-894466, 37-894467, 37-894468, Exp 06/13/2023; 37-894706, 37-894714, Exp 06/14/2023; 37-895680, 37-895682, Exp 06/19/2023; 37-896123, Exp 06/20/2023; 37-896564, 37-896579, 37-896586, Exp 06/21/2023

Other recalls by Central Admixture Pharmacy Services, Inc.

  • D-0272-2025 Class I — PHENYLephrine added to 0.9% sodium chloride, 40 mg/250 mL* (160 mcg/mL), Rx Only (February 20, 2025)
  • D-0007-2024 Class II — PHENYLephrine in 0.9% sodium chloride, 1,000 mcg/10 mL, (100 mcg/mL), 10 mL syri (September 21, 2023)
  • D-0009-2024 Class II — fentaNYL in 0.9% sodium chloride, 10 mcg/1 mL, (10 mcg/mL), 3 mL Syringe, Rx onl (September 21, 2023)
  • D-0016-2024 Class II — fentaNYL 2 mcg/mL and bupivacaine 0.0625% PF in 0.9% sodium chloride, Total Volu (September 21, 2023)
  • D-0020-2024 Class II — fentaNYL, 250 mcg/5 mL, (50 mcg/mL), 5 mL Syringe, Rx only, Repackaged by CAPS I (September 21, 2023)
  • D-0013-2024 Class II — fentaNYL in 0.9% sodium chloride, 2,500 mcg/250 mL, (10 mcg/mL), 250 mL bag, Rx (September 21, 2023)
  • D-0028-2024 Class II — HYDROmorphone in 0.9% sodium chloride, 10 mg/50 mL, (0.2 mg/mL), 50 mL Syringe, (September 21, 2023)
  • D-0018-2024 Class II — midazolam in dextrose 5%, 50 mg/50 mL, (1 mg/mL), 50 mL Syringe, Rx only, Centra (September 21, 2023)
  • D-0027-2024 Class II — HYDROmorphone in 0.9% sodium chloride, 6 mg/30 mL, (0.2 mg/mL), 30 mL Syringe, R (September 21, 2023)
  • D-0025-2024 Class II — fentaNYL, 1,250 mcg/25 mL, (50 mcg/mL), 30 mL Syringe, Rx only, Central Admixtur (September 21, 2023)